Immune modulation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
=== EC 2.7.1: Phosphotransferases with an alcohol group as acceptor === EC 2.7.1.1: hexokinase EC 2.7.1.2: glucokinase EC 2.7.1.3: ketohexokinase EC 2.7.1.4: fructokinase EC 2.7.1.5: rhamnulokinase EC 2.7.1.6: galactokinase EC 2.7.1.7: mannokinase EC 2.7.1.8: glucosamine kinase EC 2.7.1.9: deleted EC 2.7.1.10: phosphoglucokinase EC 2.7.1.11: 6-phosphofructokinase EC 2.7.1.12: gluconokinase EC 2.7.1.13: dehydrogluconokinase EC 2.7.1.14: sedoheptulokinase EC 2.7.1.15: ribokinase EC 2.7.1.16: ribulokinase EC 2.7.1.17: xylulokinase EC 2.7.1.18: phosphoribokinase EC 2.7.1.19: phosphoribulokinase EC 2.7.1.20: adenosine kinase EC 2.7.1.21: thymidine kinase EC 2.7.1.22: ribosylnicotinamide kinase EC 2.7.1.23: NAD+ kinase EC 2.7.1.24: dephospho-CoA kinase EC 2.7.1.25: adenylyl-sulfate kinase EC 2.7.1.26: riboflavin kinase EC 2.7.1.27: erythritol kinase (D-erythritol 4-phosphate-forming) EC 2.7.1.28: triokinase EC 2.7.1.29: glycerone kinase EC 2.7.1.30: glycerol kinase EC 2.7.1.31: glycerate kinase EC 2.7.1.32: choline kinase EC 2.7.1.33: pantothenate kinase EC 2.7.1.34: pantetheine kinase EC 2.7.1.35: pyridoxal kinase EC 2.7.1.36: mevalonate kinase EC 2.7.1.37: now divided into EC 2.7.11.1, EC 2.7.11.8, EC 2.7.11.9, EC 2.7.11.10, EC 2.7.11.11, EC 2.7.11.12, EC 2.7.11.13, EC 2.7.11.21, EC 2.7.11.22, EC 2.7.11.24, EC 2.7.11.25, EC 2.7.11.30 and EC 2.7.12.1 EC 2.7.1.38: now EC 2.7.11.19, phosphorylase kinase EC 2.7.1.39: homoserine kinase EC 2.7.1.40: pyruvate kinase EC 2.7.1.41: glucose-1-phosphate phosphodismutase EC 2.7.1.42: riboflavin phosphotransferase EC 2.7.1.43: glucuronokinase EC 2.7.1.44: galacturonokinase EC 2.7.1.45: 2-dehydro-3-deoxygluconokinase EC 2.7.1.46: L-arabinokinase EC 2.7.1.47: D-ribulokinase EC 2.7.1.48: uridine kinase EC 2.7.1.49: hydroxymethylpyrimidine kinase EC 2.7.1.50: hydroxyethylthiazole kinase EC 2.7.1.51: L-fuculokinase EC 2.7.1.52: fucokinase EC 2.7.1.53: L-xylulokinase EC 2.7.1.54: D-arabinokinase EC 2.7.1.55: allose kinase EC 2.7.1.56: 1-phosphofructokinase EC 2.7.1.57: deleted EC 2.7.1.58: 2-dehydro-3-deoxygalactonokinase EC 2.7.1.59: N-acetylglucosamine kinase EC 2.7.1.60: N-acylmannosamine kinase EC 2.7.1.61: acyl-phosphate—hexose phosphotransferase EC 2.7.1.62: Phosphoramidate-hexose phosphotransferase EC 2.7.1.63: polyphosphate—glucose phosphotransferase EC 2.7.1.64: inositol 3-kinase EC 2.7.1.65: scyllo-inosamine 4-kinase EC 2.7.1.66: undecaprenol kinase EC 2.7.1.67: 1-phosphatidylinositol 4-kinase EC 2.7.1.68: 1-phosphatidylinositol-4-phosphate 5-kinase EC 2.7.1.69: now covered by EC 2.7.1.191, EC 2.7.1.192, EC 2.7.1.193, EC 2.7.1.194, EC 2.7.1.195, EC 2.7.1.196, EC 2.7.1.197, EC 2.7.1.198, EC 2.7.1.199, EC 2.7.1.200 EC 2.7.1.20, EC 2.7.1.202, EC 2.7.1.203, EC 2.7.1.204, EC 2.7.1.205, EC 2.7.1.206, EC 2.7.1.207 and EC 2.7.1.208 EC 2.7.1.70: Now included in EC 2.7.11.1, non-specific serine/threonine protein kinase EC 2.7.1.71: shikimate kinase EC 2.7.1.72: streptomycin 6-kinase EC 2.7.1.73: inosine kinase EC 2.7.1.74: deoxycytidine kinase EC 2.7.1.75: Now EC 2.7.1.21 thymidine kinase EC 2.7.1.76: deoxyadenosine kinase EC 2.7.1.77: nucleoside phosphotransferase EC 2.7.1.78: polynucleotide 5′-hydroxyl-kinase EC 2.7.1.79: diphosphate—glycerol phosphotransferase EC 2.7.1.80: diphosphate—serine phosphotransferase EC 2.7.1.81: hydroxylysine kinase EC 2.7.1.82: ethanolamine kinase EC 2.7.1.83: pseudouridine kinase EC 2.7.1.84: alkylglycerone kinase EC 2.7.1.85: β-glucoside kinase EC 2.7.1.86: NADH kinase EC 2.7.1.87: streptomycin 3′′-kinase EC 2.7.1.88: dihydrostreptomycin-6-phosphate 3′α-kinase EC 2.7.1.89: thiamine kinase EC 2.7.1.90: diphosphate—fructose-6-phosphate 1-phosphotransferase EC 2.7.1.91: sphinganine kinase EC 2.7.1.92: 5-dehydro-2-deoxygluconokinase EC 2.7.1.93: alkylglycerol kinase EC 2.7.1.94: acylglycerol kinase EC 2.7.1.95: kanamycin kinase EC 2.7.1.96: deleted, Now included with EC 2.7.1.86 NADH kinase EC 2.7.1.97: deleted, Identical with EC 2.7.11.14, rhodopsin kinase EC 2.7.1.98: deleted EC 2.7.1.99: Now EC 2.7.11.2, [pyruvate dehydrogenase (acetyl-transferring)] kinase EC 2.7.1.100: S-methyl-5-thioribose kinase EC 2.7.1.101: tagatose kinase EC 2.7.1.102: hamamelose kinase EC 2.7.1.103: viomycin kinase EC 2.7.1.104: Now EC 2.7.99.1, triphosphate—protein phosphotransferase EC 2.7.1.105: 6-phosphofructo-2-kinase EC 2.7.1.106: glucose-1,6-bisphosphate synthase EC 2.7.1.107: diacylglycerol kinase EC 2.7.1.108: dolichol kinase EC 2.7.1.109: Now EC 2.7.11.31, [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase EC 2.7.1.110: Now EC 2.7.11.3, dephospho-(reductase kinase) kinase EC 2.7.1.111: Now listed as EC 2.7.11.27, [acetyl-CoA carboxylase] kinase EC 2.7.1.112: Now EC 2.7.10.2, non-specific protein-tyrosine kinase EC 2.7.1.113: deoxyguanosine kinase EC 2.7.1.114: AMP—thymidine kinase EC 2.7.1.115: Now EC 2.7.11.4, (3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)) kinase EC 2.7.1.116: Now EC 2.7.11.5, [isocitrate dehydrogenase (NADP+)] kinase EC 2.7.1.117: Now EC 2.7.11.18, myosin-light-chain kinase EC 2.7.1.118: ADP—thymidine kinase EC 2.7.1.119: hygromycin-B 7′′-O-kinase EC 2.7.1.120: Now EC 2.7.11.17, Ca2+/calmodulin-dependent protein kinase EC 2.7.1.121: phosphoenolpyruvate—glycerone phosphotransferase EC 2.7.1.122: xylitol kinase EC 2.7.1.123: Now EC 2.7.11.17, Ca2+/calmodulin-dependent protein kinase EC 2.7.1.124: Now EC 2.7.11.6, [tyrosine 3-monooxygenase] kinase EC 2.7.1.125: Now EC 2.7.11.14, rhodopsin kinase EC 2.7.1.126: Now EC 2.7.11.15, β-adrenergic-receptor kinase EC 2.7.1.127: inositol-trisphosphate 3-kinase EC 2.7.1.128: Now EC 2.7.11.27, [acetyl-CoA carboxylase] kinase EC 2.7.1.129: Now EC 2.7.11.7, myosin-heavy-chain kinase EC 2.7.1.130: tetraacyldisaccharide 4′-kinase EC 2.7.1.131: Now EC 2.7.11.29, low-density-lipoprotein receptor kinase EC 2.7.1.132: Now EC 2.7.11.28, tropomyosin kinase EC 2.7.1.133: Now included with EC 2.7.1.134, inositol-tetrakisphosphate 1-kinase EC 2.7.1.134: inositol-tetrakisphosphate 1-kinase EC 2.7.1.135: Now EC 2.7.11.26, tau-protein kinase EC 2.7.1.136: macrolide 2′-kinase EC 2.7.1.137: phosphatidylinositol 3-kinase EC 2.7.1.138: ceramide kinase EC 2.7.1.139: Now included with EC 2.7.1.134, inositol-tetrakisphosphate 1-kinase EC 2.7.1.140: inositol-tetrakisphosphate 5-kinase EC 2.7.1.141: Now EC 2.7.11.23, [RNA-polymerase]-subunit kinase EC 2.7.1.142: glycerol-3-phosphate—glucose phosphotransferase EC 2.7.1.143: diphosphate-purine nucleoside kinase EC 2.7.1.144: tagatose-6-phosphate kinase EC 2.7.1.145: deoxynucleoside kinase EC 2.7.1.146: ADP-dependent phosphofructokinase EC 2.7.1.147: ADP-dependent glucokinase EC 2.7.1.148: 4-(cytidine 5′-diphospho)-2-C-methyl-D-erythritol kinase EC 2.7.1.149: 1-phosphatidylinositol-5-phosphate 4-kinase EC 2.7.1.150: 1-phosphatidylinositol-3-phosphate 5-kinase EC 2.7.1.151: inositol-polyphosphate multikinase EC 2.7.1.152: Now EC 2.7.4.21, inositol-hexakisphosphate kinase EC 2.7.1.153: phosphatidylinositol-4,5-bisphosphate 3-kinase EC 2.7.1.154: phosphatidylinositol-4-phosphate 3-kinase EC 2.7.1.155: Now EC 2.7.4.24, diphosphoinositol-pentakisphosphate kinase EC 2.7.1.156: adenosylcobinamide kinase EC 2.7.1.157: N-acetylgalactosamine kinase EC 2.7.1.158: inositol-pentakisphosphate 2-kinase EC 2.7.1.159: inositol-1,3,4-trisphosphate 5/6-kinase EC 2.7.1.160: 2′-phosphotransferase EC 2.7.1.161: CTP-dependent riboflavin kinase EC 2.7.1.162: N-acetylhexosamine 1-kinase EC 2.7.1.163: hygromycin B 4-O-kinase EC 2.7.1.164: O-phosphoseryl-tRNASec kinase EC 2.7.1.165: glycerate 2-kinase EC 2.7.1.166: 3-deoxy-D-manno-octulosonic acid kinase EC 2.7.1.167: D-glycero-β-D-manno-heptose-7-phosphate kinase EC 2.7.1.168: D-glycero-α-D-manno-heptose-7-phosphate kinase EC 2.7.1.169: pantoate kinase EC 2.7.1.170: anhydro-N-acetylmuramic acid kinase EC 2.7.1.171: protein-fructosamine 3-kinase EC 2.7.1.172: protein-ribulosamine 3-kinase EC 2.7.1.173: nicotinate riboside kinase EC 2.7.1.174: diacylglycerol kinase (CTP dependent) EC 2.7.1.175: maltokinase EC 2.7.1.176: UDP-N-acetylglucosamine kinase EC 2.7.1.177: L-threonine kinase EC 2.7.1.178: 2-dehydro-3-deoxyglucono/galactono-kinase EC 2.7.1.179: kanosamine kinase EC 2.7.1.180: FAD:protein FMN transferase EC 2.7.1.181: polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol kinase EC 2.7.1.182: phytol kinase EC 2.7.1.183: glycoprotein-mannosyl O6-kinase EC 2.7.1.184: sulfofructose kinase EC 2.7.1.185: mevalonate 3-kinase EC 2.7.1.186: mevalonate-3-phosphate 5-kinase EC 2.7.1.187: acarbose 7IV-phosphotransferase EC 2.7.1.188: 2-epi-5-epi-valiolone 7-kinase EC 2.7.1.189: autoinducer-2 kinase EC 2.7.1.190: aminoglycoside 2′′-phosphotransferase EC 2.7.1.191: protein-N π-phosphohistidine—D-mannose phosphotransferase EC 2.7.1.192: protein-N π-phosphohistidine—N-acetylmuramate phosphotransferase EC 2.7.1.193: protein-N π-phosphohistidine—N-acetyl-D-glucosamine phosphotransferase EC 2.7.1.194: protein-N π-phosphohistidine—L-ascorbate phosphotransferase EC 2.7.1.195: protein-N π-phosphohistidine—2-O-α-mannosyl-D-glycerate phosphotransferase EC 2.7.1.196: protein-N π-phosphohistidine—N,N′-diacetylchitobiose phosphotransferase EC 2.7.1.197: protein-Nπ'-phosphohistidine—D-mannitol phosphotransferase EC 2.7.1.198: protein-N π-phosphohistidine—D-sorbitol phosphotransferase EC 2.7.1.199: protein-N π-phosphohistidine—D-glucose phosphotransferase EC 2.7.1.200: protein-N π-phosphohistidine—galactitol phosphotransferase EC 2.7.1.201: protein-N π-phosphohistidine—trehalose phosphotransferase EC 2.7.1.202: protein-N π-phosphohistidine—D-fructose phosphotransferase EC 2.7.1.203: protein-N π-phosphohistidine—D-glucosaminate phosphotransferase EC 2.7.1.204: protein-N π-phosphohistidine—D-galactose phosphotransferase EC 2.7.1.205: protein-N π-phosphohistidine—cellobiose phosphotransferase EC 2.7.1.206: protein-N π-phosphohistidine—L-sorbose phosphotransferase EC 2.7.1.207: protein-N π-phosphohistidine—lactose phosphotransferase EC 2.7.1.208: protein-N π-phosphohistidine—maltose phosphotransferase EC 2.7.1.209: L-erythrulose 1-kinase EC 2.7.1.210: D-erythrulose 4-kinase EC 2.7.1.211: protein-N π-phosphohistidine—sucrose phosphotransferase EC 2.7.1.212: α-D-ribose-1-phosphate 5-kinase (ADP) EC 2.7.1.213: cytidine kinase EC 2.7.1.214: C7-cyclitol 7-kinase EC 2.7.1.215: erythritol kinase (D-erythritol 1-phosphate-forming) EC 2.7.1.216: farnesol kinase EC 2.7.1.217: 3-dehydrotetronate 4-kinase EC 2.7.1.218: fructoselysine 6-kinase EC 2.7.1.219: D-threonate 4-kinase EC 2.7.1.220: D-erythronate 4-kinase EC 2.7.1.221: N-acetylmuramate 1-kinase EC 2.7.1.222: 4-hydroxytryptamine kinase EC 2.7.1.223: aminoimidazole riboside kinase EC 2.7.1.224: cytidine diphosphoramidate kinase EC 2.7.1.225: L-serine kinase (ATP) EC 2.7.1.226: L-serine kinase (ADP) EC 2.7.1.227: inositol phosphorylceramide synthase EC 2.7.1.228: mannosyl-inositol-phosphoceramide inositolphosphotransferase EC 2.7.1.229: deoxyribokinase EC 2.7.1.230: amicoumacin kinase EC 2.7.1.231: 3-oxoisoapionate kinase EC 2.7.1.232: levoglucosan kinase EC 2.7.1.233: apulose kinase
==== Deficit in consolidation of memory traces ==== α-CaMKII heterozygous mice express half the normal protein level as the wild-type level. These mice showed normal memory storage in the hippocampus, but deficits in consolidation of memory in the cortex.
LEDs are made in different packages for different applications. A single or a few LED junctions may be packed in one miniature device for use as an indicator or pilot lamp. An LED array may include controlling circuits within the same package, which may range from a simple resistor, blinking or color changing control, or an addressable controller for RGB devices. Higher-powered white-emitting devices will be mounted on heat sinks and will be used for illumination. Alphanumeric displays in dot matrix or bar formats are widely available. Special packages permit connection of LEDs to optical fibers for high-speed data communication links.
With the encouragement of Ollendorff (promising that a US organization called "The Friends of the Technion" would support Feher's studies), he applied for 50 universities in the US, and only two were willing to accept him. He could not afford the voyage to US so he started a small production line for devices with piezoelectric crystals, mainly microphones. In December 1946 he arrived to New York, where he realized that "Friends of the Technion" would not fund his degree. With poor means he attended the University of California, Berkeley, where he received his bachelor's degree in engineering physics (1950), master's degree in electrical engineering (1951) and doctorate (1954).
==== Detecting malicious use ==== Scholars and government agencies have expressed concerns that AI systems could be used to help malicious actors to build weapons, manipulate public opinion, or automate cyber attacks. These worries are a practical concern for companies like OpenAI which host powerful AI tools online. In order to prevent misuse, OpenAI has built detection systems that flag or restrict users based on their activity. In 2026, a financially motivated threat actor used open-source AI agents to automate a large-scale cyberattack campaign against online retailers. Strix was used for vulnerability discovery, Cairn for autonomous exploitation, and Hermes for attack orchestration. Researchers reported that at least 27 organizations were compromised and more than 600,000 payment card records were stolen from two victim retailers.
Sources: en.wikipedia.org
It is likely that this data was used to develop the initial protocols for state-sanctioned lethal injection, according to which one gram of thiopental was used to induce the coma. Most states use 5 grams to be absolutely certain the dosage is effective. Pentobarbital was introduced at the end of 2010 due to a shortage of sodium thiopental, and has since become the primary sedative in lethal injections in the United States. Barbiturates are the same class of drug used in medically assisted suicide. In euthanasia protocols, the typical dose of thiopental is 1.5 grams; the Dutch Euthanasia protocol indicates 1-1.5 grams or 2 grams in case of high barbiturate tolerance. The dose used for capital punishment is therefore about 3 times more than the dose used in euthanasia.
Malic acid is also used to determine apple ripeness for harvesting, as its concentration decreases as the fruit ripens. Lactic acid is also commonly found in cider, and it is mainly formed from malo-lactic fermentation, a process that converts malic acid into lactic acid. This process rounds out the flavour of the cider while reducing a lot of the acidity and producing carbon dioxide as well. Other acids such as citric acid can be used to add taste after fermentation, but these acids are not typically found in high concentration in apples naturally. Most of the natural sugar in apples are used up in the fermentation process and are converted into alcohol, and carbon dioxide. If the fermentation goes all the way, the cider will have no perceivable residual sugar and be dry. This means that the cider will not taste sweet, and might show more bitterness, or acidity. Ciders are made in many parts of Europe and in the United States and each country has different representations of cider with different flavour compounds. Keeving is a traditional method of fermentation with low amounts of nitrogen in French and English ciders that is intended to slow down the rate of fermentation in hopes of retaining high esters as well as retaining some residual sugar in the bottled cider to increase effervescence in the ageing process. Ciders can be back sweetened, after fermentation is complete to add a sweet taste and balance out acids, tannins, and bitterness. Natural sugar can be used but this can restart fermentation in a bottle if not filtered correctly.
A Scatchard plot (Rosenthal plot) can be used to show radioligand affinity. In this type of plot, the ratio of Bound/Free radioligand is plotted against the Bound radioligand. The slope of the line is equal to the negative reciprocal of the affinity constant (K). The intercept of the line with the X axis is an estimate of Bmax. The Scatchard plot can be standardized against an appropriate reference so that there can be a direct comparison of receptor density in different studies and tissues. This sample plot indicates that the radioligand binds with a single affinity. If the ligand were to have bound to multiple sites that have differing radioligand affinities, then the Scatchard plot would have shown a concave line instead.
==== Russia/Belarus MEU FDP Rule ==== Russia and Belarus are subject to the same restrictions as the military end use/user rule, with more expansive coverage that includes foreign-produced items made using U.S.-origin software or technology, manufactured by plants or major components that are products of the U.S.
Sources: en.wikipedia.org
All of the opioids can cause side effects. Adverse reactions in patients taking opioids include reinforcement disorders, nausea and vomiting, drowsiness, itching, dry mouth, dizziness, and constipation. In older adults, opioid use is associated with increased adverse effects such as "sedation, nausea, vomiting, constipation, urinary retention, and falls". As a result, older adults taking opioids are at greater risk for injury. Opioids do not cause any specific organ toxicity, unlike many other drugs, such as aspirin and paracetamol. They are not associated with upper gastrointestinal bleeding and kidney toxicity. Prescription of opioids for acute low back pain and management of osteoarthritis seem to have long-term adverse effects
=== Names === Estrogens, conjugated is the generic name of the drug and its USPTooltip United States Pharmacopeia and JANTooltip Japanese Accepted Name. It is also known as conjugated estrogens or as conjugated equine estrogens. The brand name Premarin is a contraction of "pregnant mares' urine". CEEs are marketed under a large number of brand names throughout the world. The major brand name of the natural form of CEEs manufactured from the urine of pregnant mares is Premarin. Major brand names of fully synthetic versions of CEEs include Cenestin and Enjuvia in the United States and C.E.S. and Congest in Canada. CEEs are also formulated in combination with progestins. Major brand names of CEEs in combination with medroxyprogesterone acetate include Prempro and Premphase in the United States, Premplus in Canada, Premique in the United Kingdom and Ireland, Premia in Australia and New Zealand, and Premelle in South Africa. Prempak-C is a combination of CEEs and norgestrel which is used in the United Kingdom and Ireland, and Prempak N is a combination of CEEs and medrogestone which is used in South Africa. Many of the aforementioned brand names are also used in other, non-English-speaking countries.
The basic principle of freeze drying is the removal of water by sublimation. Since the mass production of instant coffee began in post-WWII America, freeze-drying, which produces a flaky powder, has grown in popularity; it is more expensive than spray drying. Its long processing times may make it unsuitable for small-scale production. In this process, coffee extract is frozen, rapidly to prevent the formation of larger ice crystals, then milled into small granules, which are sifted to ensure a uniform size and added to an industrial freeze dryer. The previously frozen water expands the coffee granules to ten times their previous volume through sublimation. The freeze-dried granules are then removed from the chamber and packaged for sale.
Movement between towns was by escorted convoy, and the roads in the north were closed to civilian traffic between six in the evening and half past seven in the morning. White civilians and administrators from Oshakati, Ondangwa, and Rundu began routinely carrying arms, and never ventured far from their fortified neighbourhoods.
nucleotide Also nucleoside monophosphate (NMP). An organic molecule that serves as the fundamental monomer or subunit of nucleic acid polymers, including RNA and DNA. Each nucleotide is composed of three connected functional groups: a nitrogenous base, a five-carbon sugar (either ribose or deoxyribose), and a single phosphate group. Though technically distinct, the term "nucleotide" is often used interchangeably with nitrogenous base, nucleobase, and base pair when referring to the sequences that make up nucleic acids. Compare nucleoside.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.